Bio-View Ltd (TLV:BIOV)
Israel · Delayed Price · Currency is ILS · Price in ILA 129.80
-2.00 (-1.52%)
Jun 10, 2026, 2:23 PM IDT
Bio-View Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 19.93 | 25.66 | 34.77 | 29.15 | 30.51 | |
Revenue Growth (YoY) | -22.31% | -26.21% | 19.29% | -4.48% | 17.54% |
Cost of Revenue | 10.41 | 10.09 | 13.39 | 12.48 | 12.93 |
Gross Profit | 9.52 | 15.56 | 21.38 | 16.67 | 17.59 |
Selling, General & Admin | 12.62 | 11.88 | 12.83 | 11.72 | 9.7 |
Research & Development | 4.7 | 6.66 | 8.41 | 4.85 | 5.33 |
Other Operating Expenses | -0.05 | 0 | - | - | - |
Operating Expenses | 17.27 | 18.54 | 21.24 | 16.57 | 15.03 |
Operating Income | -7.75 | -2.97 | 0.14 | 0.1 | 2.56 |
Interest Expense | -0.12 | -0.22 | -0.31 | -0.24 | -0.23 |
Interest & Investment Income | 0.06 | 0.39 | 0.44 | 0.03 | 0.02 |
Currency Exchange Gain (Loss) | -0.07 | 0.1 | 0.14 | 1.05 | -0.59 |
Other Non Operating Income (Expenses) | -1.15 | -0.16 | -0.1 | -0.07 | -0.06 |
EBT Excluding Unusual Items | -9.03 | -2.86 | 0.3 | 0.88 | 1.7 |
Gain (Loss) on Sale of Investments | -0.11 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | -0.01 |
Other Unusual Items | - | - | 0.49 | - | 0.99 |
Pretax Income | -9.15 | -2.86 | 0.8 | 0.88 | 2.68 |
Income Tax Expense | 6.19 | 0.29 | 0.41 | 0.29 | 0.5 |
Net Income | -15.33 | -3.15 | 0.38 | 0.59 | 2.18 |
Net Income to Common | -15.33 | -3.15 | 0.38 | 0.59 | 2.18 |
Net Income Growth | - | - | -34.75% | -73.12% | 147.06% |
Shares Outstanding (Basic) | 14 | 13 | 14 | 14 | 14 |
Shares Outstanding (Diluted) | 14 | 13 | 14 | 14 | 14 |
Shares Change (YoY) | 2.13% | -5.22% | 0.75% | -0.49% | -0.60% |
EPS (Basic) | -1.13 | -0.24 | 0.03 | 0.04 | 0.16 |
EPS (Diluted) | -1.13 | -0.24 | 0.03 | 0.04 | 0.16 |
EPS Growth | - | - | -32.98% | -72.99% | 160.44% |
Free Cash Flow | -3.11 | -3.14 | -0.12 | 0.51 | 2.59 |
Free Cash Flow Per Share | -0.23 | -0.24 | -0.01 | 0.04 | 0.18 |
Gross Margin | 47.76% | 60.66% | 61.48% | 57.20% | 57.63% |
Operating Margin | -38.89% | -11.59% | 0.39% | 0.35% | 8.38% |
Profit Margin | -76.93% | -12.27% | 1.10% | 2.01% | 7.16% |
Free Cash Flow Margin | -15.60% | -12.24% | -0.35% | 1.75% | 8.48% |
EBITDA | -7.35 | -2.68 | 1.96 | 1.6 | 4.03 |
EBITDA Margin | -36.86% | -10.43% | 5.62% | 5.48% | 13.22% |
D&A For EBITDA | 0.41 | 0.3 | 1.82 | 1.5 | 1.48 |
EBIT | -7.75 | -2.97 | 0.14 | 0.1 | 2.56 |
EBIT Margin | -38.89% | -11.59% | 0.39% | 0.35% | 8.38% |
Effective Tax Rate | - | - | 51.94% | 32.91% | 18.60% |
Advertising Expenses | 0.21 | 0.22 | 0.12 | 0.17 | 0.04 |